Thank you for attending Next-Generation Degraders and Glues! Join the mailing list for next year’s event.
The ubiquitin-proteasome, lysosome and autophagy systems are all well-controlled, selective degradation pathways that are key cellular regulators in cancer, CNS and other diseases. A new generation of hetero bi-functional chimeras and
small molecule monovalent degraders are being developed to hijack these systems for targeted protein degradation or stabilization. These molecules that include Proteolysis-targeting chimeras (PROTACs) and molecular glues are being
used to seek out previously “undruggable” targets for therapeutic intervention. However, challenges do exist in terms of specificity, stability, biodistribution and penetration of these degrader molecules.
The 2nd Annual conference on Next-Generation Degraders & Glues brings together experts in the field to discuss these new therapeutic modalities, as well as issues underlying the use of targeted degradation as a new
therapeutic approach.
View the agenda, register, or become a sponsor!
Join the Community
CONTENT SUGGESTIONS
For program questions or suggestions,
please contact:
Tanuja Koppal, PhD
Senior Conference Director
tkoppal@healthtech.com
PARTNERING & SPONSORSHIP
For partnering and sponsorship info,
please contact:
Rod Eymael
Business Development Manager
T: (+1) 781-247-6286
reymael@healthtech.com
MEDIA ASSOCIATION
For media and association partnerships,
please contact:
Amberly Ortkiese
Marketing Manager
aortkiese@healthtech.com
View Current Media Partners